A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement

American Journal of Obstetrics and Gynecology

Volumn 215, Issue 5, 2016, Pages 599.e1-599.e6

  Turok, David K ^a   Eisenberg, David L ^b   Teal, Stephanie B ^c   Keder, Lisa M ^d   Creinin, Mitchell D ^e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chlamydia; contraception; endometritis; gonorrhea; intrauterine device; intrauterine system; levonorgestrel; Liletta; pelvic infection; pelvic inflammatory disease

Indexed keywords

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; CHLAMYDIASIS; CONFERENCE PAPER; CONTROLLED STUDY; DEVICE REMOVAL; DEVICE SAFETY; ENDOMETRITIS; FEMALE; GONORRHEA; HOSPITAL PATIENT; HUMAN; INFECTION RISK; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MAJOR CLINICAL STUDY; MULTIPARA; NULLIPARA; OUTPATIENT CARE; PELVIC EXAMINATION; PELVIC INFLAMMATORY DISEASE; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; CHLAMYDIA INFECTIONS; INTRAUTERINE CONTRACEPTIVE DEVICE; MIDDLE AGED; PELVIC INFECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUALLY TRANSMITTED DISEASES; TIME FACTOR; YOUNG ADULT;

CONTRACEPTIVE AGENT; LEVONORGESTREL;

ADOLESCENT; ADULT; CHLAMYDIA INFECTIONS; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRITIS; FEMALE; GONORRHEA; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MIDDLE AGED; PELVIC INFECTION; PELVIC INFLAMMATORY DISEASE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUALLY TRANSMITTED DISEASES; TIME FACTORS; YOUNG ADULT;

EID: 84979697579     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.05.017     Document Type: Conference Paper

References (28)

1. 1 Yoost, J., Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States. Patient Prefer Adherence 8 (2014), 947–957.
2. 2 Swanson, K.J., Gossett, D.R., Fournier, M., Pediatricians' beliefs and prescribing patterns of adolescent contraception: a provider survey. J Pediatr Adolesc Gynecol 26 (2013), 340–345.
3. 3 Rubin, S.E., Campos, G., Markens, S., Primary care physicians' concerns may affect adolescents' access to intrauterine contraception. J Prim Care Community Health 4 (2013), 216–219.
4. 4 Stanwood, N.L., Garrett, J.M., Konrad, T.R., Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. Obstet Gynecol 99 (2002), 275–280.
5. 5 Tyler, C.P., Whiteman, M.K., Zapata, L.B., Curtis, K.M., Hillis, S.D., Marchbanks, P.A., Health care provider attitudes and practices related to intrauterine devices for nulliparous women. Obstet Gynecol 119 (2012), 762–771.
6. 6 Moreau, C., Bohet, A., Hassoun, D., Ringa, V., Bajos, N., FECOND Group. IUD use in France: women's and physician's perspectives. Contraception 89 (2014), 9–16.
7. 7 Goodman, S., Hendlish, S.K., Benedict, C., Reeves, M.F., Pera-Floyd, M., Foster-Rosales, A., Increasing intrauterine contraception use by reducing barriers to post-abortal and interval insertion. Contraception 78 (2008), 136–142.
8. 8 Walsh, T., Grimes, D., Frezieres, R., et al. Randomized controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet 351 (1998), 1005–1008.
9. 9 Nelson, A., Apter, D., Hauck, B., et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol 122 (2013), 1205–1213.
10. 10 Sufrin, C.B., Postlethwaite, D., Armstrong, M.A., Merchant, M., Wendt, J.M., Steinauer, J.E., Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol 120 (2012), 1314–1321.
11. 11 Walsh, T.L., Bernstein, G.S., Grimes, D.A., Frezieres, R., Bernstein, L., Coulson, A.H., Effect of prophylactic antibiotics on morbidity associated with IUD insertion: results of a pilot randomized controlled trial. Contraception 50 (1994), 319–327.
12. 12 Birgisson, N.E., Zhao, Q., Secura, G.M., Madden, T., Peipert, J.F., Positive testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users. J Womens Health (Larchmt) 24 (2015), 354–359.
13. 13 Mohllajee, A.P., Curtis, K.M., Peterson, H.B., Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 73 (2006), 145–153.
14. 14 Eisenberg, D.L., Schreiber, C.A., Turok, D.K., Teal, S.B., Westhoff, C.L., Creinin, M.D., Three year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception 92 (2015), 10–16.
15. 15 Workowski, K.A., Berman, S., Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 59 (2010), 1–110.
16. 16 Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2014. 2015, US Department of Health and Human Services, Atlanta (GA).
17. 17 Farley, T.M., Rosenberg, M.J., Rowe, P.J., Chen, J.H., Meirik, O., Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 339 (1992), 785–788.
18. 18 Andersson, K., Odlind, V., Rybo, G., Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 49 (1994), 56–72.
19. 19 American College of Obstetricians and Gynecologists. Long-acting reversible contraception: implants and intrauterine devices. Practice bulletin no. 121. Obstet Gynecol 118 (2011), 184–196.
20. 20 Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC). US selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep 62 (2013), 1–60.
21. 21 Luchowski, A.T., Anderson, B.L., Power, M.L., Raglan, G.B., Espey, E., Schulkin, J., Obstetrician-gynecologists and contraception: practice and opinions about the use of IUDs in nulliparous women, adolescents and other patient populations. Contraception 89 (2014), 572–577.
22. 22 Biggs, M.A., Arons, A., Turner, R., Brindis, C.D., Same-day LARC insertion attitudes and practices. Contraception 88 (2013), 629–635.
23. 23 Luchowski, A.T., Anderson, B.L., Power, M.L., Raglan, G.B., Espey, E., Schulkin, J., Obstetrician-gynecologists and contraception: long-acting reversible contraception practices and education. Contraception 89 (2014), 578–583.
24. 24 Bergin, A., Tristan, S., Terplan, M., Gilliam, M.L., Whitaker, A.K., A missed opportunity for care: two-visit IUD insertion protocols inhibit placement. Contraception 86 (2012), 694–697.
25. 25 Biggs, M.A., Harper, C.C., Brindis, C.D., California family planning health care providers' challenges to same-day long-acting reversible contraception provision. Obstet Gynecol 126 (2015), 338–345.
26. 26 Bohm, M.K., Newman, L., Satterwhite, C.L., Tao, G., Weinstock, H.S., Pelvic inflammatory disease among privately insured women, United States, 2001–2005. Sex Transm Dis 37 (2010), 131–136.
27. 27 Rohrbeck, P., Pelvic inflammatory disease among female recruit trainees, active component, US Armed Forces, 2002-2012. MSMR 20 (2013), 15–18.
28. 28 Humes, K.R., Jones, N.A., Ramirez, R.R., Overview of race and Hispanic origin: 2010. 2011, US Census Bureau, Washington (DC).